Your browser doesn't support javascript.
loading
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni, Jie; Zhou, Lei-Lei; Ding, Li; Zhao, Xia; Cao, Haixia; Fan, Fan; Li, Huizi; Lou, Rui; Du, Yuanyuan; Dong, Shuchen; Liu, Siwen; Wang, Zhuo; Ma, Rong; Wu, Jianzhong; Feng, Jifeng.
Afiliação
  • Ni J; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Zhou LL; Department of Oncology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, China.
  • Ding L; The Jiangsu Province Research Institute for Clinical Medicine, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
  • Zhao X; Department of Oncology, Yancheng First People's Hospital, Nanjing Medical University, Yancheng, Jiangsu, China.
  • Cao H; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Fan F; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Li H; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Lou R; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Du Y; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Dong S; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Liu S; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Wang Z; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Ma R; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Wu J; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
  • Feng J; Nanjing Medical University Affiliated Cancer Hospital, Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China. Electronic address: jifeng_feng@163.com.
Exp Cell Res ; 361(2): 246-256, 2017 12 15.
Article em En | MEDLINE | ID: mdl-29080795
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Adenocarcinoma / Regulação Neoplásica da Expressão Gênica / Tiazolidinedionas / PPAR gama / Inibidores de Proteínas Quinases / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Revista: Exp Cell Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Adenocarcinoma / Regulação Neoplásica da Expressão Gênica / Tiazolidinedionas / PPAR gama / Inibidores de Proteínas Quinases / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Revista: Exp Cell Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: China